Mylan, Inc, the makers of EpiPen have run afoul of US Federal regulators, due to the way the product has been sold to the Medicaid system. EpiPen is an injector device, designed to provide possibly life-saving assistance to those suffering from severe allergic reactions (as seen on TV, via numerous commercials).
The problem is that the Epipen product has allegedly been classified incorrectly, leading to overcharges to the Medicaid system. This follows recent accusations that the company has raised EpiPen prices unreasonably over the last several years.
Since Mylan bought the rights to EpiPen in 2007, it has raised the price on 15 separate occasions, bringing the current list price to $608 for a two-pack up from about $50 a pen in 2007. That’s an increase of more than 500 percent, which easily beats inflation.